INTRODUCTION
Latent Autoimmune Diabetes of Adult (LADA) is an autoimmune disorder characterised by autoantibodies against the pancreatic islet cells; however, unlike type 1 diabetes mellitus, the progression of LADA is slow and the affected individual usually comes to medical attention during adulthood. It is also known as type 1.5 diabetes mellitus since it shares features of both type 1 and type 2 Diabetes Mellitus. 1 Affected patients are generally non-obese, with low magnitude hyperglycaemia and low or near normal c-peptide values. The diagnosis of LADA is made if there is evidence of adult onset of disease with positive circulating antibodies directed against pancreatic islets and the patient does not require insulin treatment for several months after diagnosis. 6 An acute hyperglycaemic complication in the form of diabetic ketoacidosis is an unusual first presenting manifestation of this disease, with very few cases recorded in medical literature. 9, 10 We hereby describe the unusual case of a 40-year-old housewife who was subsequently diagnosed to be suffering from LADA and presented with diabetic ketoacidosis as the initial presentation of LADA.
CASE SUMMARY
A 40-year-old housewife was admitted with the complaints of recent onset pain abdomen, associated with on and off nausea and vomiting for the last 2 days. It was described as a diffuse pain, mild to moderate in intensity and did not relieve following vomiting or passage of stool/flatus. Her husband had also noticed drowsiness since morning, following which he had rushed her to the emergency department. Past history was non-contributory except for a history of hypothyroidism for which she was on levothyroxine replacement therapy. There was no family history of diabetes or any other chronic illness. On examination, she was drowsy (GCS = 13/15) with a pulse rate was 90/min and acidotic Kussumaul's pattern of respiration; her respiratory rate was 26/ min and blood pressure was 130/80 mm Hg. She was afebrile while her body mass index (BMI) was calculated to be 28 kg/m 2 . Abdominal examination did not reveal any organomegaly or a palpable lump. The remaining general and systemic examination was within normal limits. There were no signs of acanthosis nigricans. Her laboratory investigations including an arterial blood gas analysis revealed the following: Random blood glucose = 540mg/dl, haemoglobin = 11.3 g/ dl, total leucocyte count = 12,300/mm 3 (N = 70%, L = 25%), sodium = 130 mmol/l, potassium = 3.8 mmol/l, chloride = 96 mmol/l, bicarbonate = 12 mmol/l, creatinine = 1mg/dl, urea = 30 mg/dl, calcium (total) = 8.9 mg/dl, pH = 7.23, pCO 2 = 24, SpO 2 = 96%, pO 2 = 86 (on O 2 mask), lactate = 1mmol/l, amylase = 30U/L, lipase = 20 U/L. Her urine sample was positive for glucose and 3+ for ketones, while her HbA1C was 10.3%. With the above investigations, we diagnosed her to have diabetic ketoacidosis. She was treated with intravenous fluids, insulin and prophylactic antibiotics according to standard protocols while her vitals were monitored rigorously. Over the next 36 h, her sensorium improved, her blood glucose levels fell to 180 mg/dl and she reported improvement in her abdominal symptoms. Gradually she resumed oral intake with liquid diet first followed by semi-solid diet, hence we shifted her to subcutaneous basal-bolus insulin regimen comprising pre-meal regular Insulin thrice a day and injection glargine at bedtime. We subjected her to further investigations to determine the nature of her diabetes mellitus. Ultrasound study of the abdomen was within normal limits. Fasting c-peptide levels were low (0.2ng/ml), while she had high titres of glutamic acid decarboxylase-65 (GAD-65) antibodies (> 50U/ ml). There were no signs of diabetic retinopathy on fundus examination. The patient was hence diagnosed as suffering from Latent Autoimmune Diabetes of Adult (LADA). She was discharged on subcutaneous Insulin regimen after explaining the nature of her disease, possible complications and hypoglycaemia management at home. She was compliant with her medications and also implemented lifestyle changes. On follow up, she maintained good glycaemic control and her HbA1C reduced to 7.4% after 6 months.
DISCUSSION
Latent Autoimmune Diabetes of Adult (LADA) is a variant of diabetes mellitus in which beta cell failure is slow to develop despite the presence of antibodies against pancreatic islet cells. Also known as type 1.5 diabetes mellitus 1 since it shares characteristics of both type 1 and type 2 diabetes mellitus, the onset of LADA is in adult life and initially may not be insulin-requiring, hence leading the patient to be misdiagnosed as type 2 diabetes mellitus. Such patients have islet autoantibodies, most commonly glutamic acid decarboxylase (GAD) antibody, low or near normal c-peptide secretion and gradual progression to Insulin dependency, resembling type 1 diabetes mellitus. 2 However, they might also exhibit elevated glucagon levels and Insulin resistance similar to patients with type 2 diabetes mellitus. 3 The clinical features of LADA resemble those of type 1 and type 2 diabetes mellitus. hypertension, CAD, dyslipidaemia and obesity are less prevalent in LADA compared to type 2 diabetes mellitus. Insulin resistance has been reported to occur less commonly in LADA, comparable with type 1 diabetes mellitus. 4 Though LADA is associated with HLA phenotypes, it is less marked compared to type 1 diabetes mellitus which might explain the slow progression of beta cell destruction and late onset of the disease. 5 LADA is diagnosed according to the following clinical criteria recommended by the Immunology of diabetes society: 6 • Adult age at onset of diabetes. • Lack of insulin requirement for at least 6 months after diagnosis.
•
The presence of at least 1 circulating autoantibody [autoantibodies to glutamic acid decarboxylase 65 (GAD -65)/islet cell cytoplasm (ICA)/tyrosine phosphatase-like protein (IA-2A)/insulin (IAA)]. There are no recommendations as regards the treatment of LADA. It mostly focusses on attaining normoglycaemia, preventing complications and beta cell protection. Most patients are misdiagnosed and treated as patients of type 2 diabetes mellitus, 7 mainly with lifestyle modification and oral hypoglycaemic agents. Once they stop responding to these drugs, patients are switched over to insulin therapy. 8 Immunomodulatory agents may be beneficial, but clinical trials are yet to demonstrate this fact. Patients with LADA generally do not present with acute hyperglycaemic complications like diabetic ketoacidosis at presentation owing to slow progression of beta cell failure. There have been very few case reports highlighting such a rare presentation of LADA. 9, 10 Overall LADA must be approached as a separate entity from type 1 diabetes mellitus and type 2 diabetes mellitus. Early initiation of insulin delays the progression of beta cell failure and helps in preventing the emergence of complications like diabetic ketoacidosis. Hence the clinician must carefully rule out LADA in adult onset diabetic patients since the management strategy for LADA differs from that of type 2 diabetes mellitus.
CONCLUSION
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